Is IPCIF or GBDC a better dividend investment in 2026?

IPCIF currently yields 1333.33% with a 5% 5-year dividend growth rate. GBDC yields 11.86% with 5% growth. The better choice depends on your goal: IPCIF offers higher current income.

What is the dividend yield difference between IPCIF and GBDC?

IPCIF has a forward dividend yield of 1333.33% ($2.00/share annually). GBDC yields 11.86% ($1.50/share annually). The yield gap is 1321.47 percentage points.

Home › Compare › IPCIF vs GBDC

IPCIF vs GBDC: Dividend Comparison 2026

IPCIF yields 1333.33% · GBDC yields 11.86%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 IPCIF wins by $241528679.76M in total portfolio value

INVESTMENT

TIME HORIZON10 years

IPCIF

● Live price

1333.33%

Share price

$0.15

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$241528700.61M

Annual income

$210,475,860,072,406.56

Full IPCIF calculator →

GBDC

● Live price

11.86%

Share price

$12.65

Annual div

$1.50

5Y div CAGR

51.1%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$20.85M

Annual income

$16,450,733.83

Full GBDC calculator →

Portfolio growth — IPCIF vs GBDC

📍 IPCIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	IPCIF	GBDC
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, IPCIF + GBDC cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

IPCIF pays

GBDC pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPCIF

Annual income on $10K today (after 15% tax)

$113,333.33/yr

After 10yr DRIP, annual income (after tax)

$178,904,481,061,545.56/yr

GBDC

Annual income on $10K today (after 15% tax)

$1,007.91/yr

After 10yr DRIP, annual income (after tax)

$13,983,123.76/yr

At 15% tax rate, IPCIF beats the other by $178,904,467,078,421.80/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPCIF + GBDC for your $10,000?

IPCIF: 50%GBDC: 50%

100% GBDC50/50100% IPCIF

Portfolio after 10yr

$120764360.73M

Annual income

$105,237,938,261,570.20/yr

Blended yield

87.14%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

IPCIF

No analyst data

Altman Z

-111.3

Piotroski

4/9

GBDC

Analyst Ratings

Buy

Hold

Consensus: Buy

Price Target

$14.00

+10.7% upside vs current

Range: $13.00 — $15.00

Altman Z

0.6

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPCIF buys

GBDC buys

No recent congressional trades found for IPCIF or GBDC in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricIPCIFGBDC

Forward yield	1333.33% ✓	11.86%
Annual dividend / share	$2.00 ✓	$1.50
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	51.1% ✓
Portfolio after 10y	$241528700.61M ✓	$20.85M
Annual income after 10y	$210,475,860,072,406.56 ✓	$16,450,733.83
Total dividends collected	$239239876.27M ✓	$20.43M
Payment frequency	quarterly	quarterly
Sector	Stock	BDC

Year-by-year: IPCIF vs GBDC ($10,000, DRIP)

Year	IPCIF Portfolio	IPCIF Income/yr	GBDC Portfolio	GBDC Income/yr	Gap
1← crossover	$144,033	$133,333.33	$12,492	$1,791.70	+$131.5K → IPCIF
2	$1,948,924	$1,794,807.89	$16,527	$3,160.58	+$1.93M → IPCIF
3	$24,782,219	$22,696,870.86	$23,588	$5,904.90	+$24.76M → IPCIF
4	$296,245,945	$269,728,970.81	$37,141	$11,901.65	+$296.21M → IPCIF
5	$3,330,378,004	$3,013,394,842.54	$66,205	$26,463.38	+$3330.31M → IPCIF
6	$35,223,684,321	$31,660,179,856.69	$137,452	$66,612.65	+$35223.55M → IPCIF
7	$350,636,384,108	$312,947,041,885.16	$342,372	$195,298.53	+$350636.04M → IPCIF
8	$3,286,630,500,315	$2,911,449,569,318.85	$1,053,292	$686,954.33	+$3286629.45M → IPCIF
9	$29,021,346,295,663	$25,504,651,660,325.88	$4,111,439	$2,984,416.95	+$29021342.18M → IPCIF
10	$241,528,700,608,766	$210,475,860,072,406.56	$20,849,974	$16,450,733.83	+$241528679.76M → IPCIF

IPCIF vs GBDC: Complete Analysis 2026

IPCIF — Stock

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Full IPCIF Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →

📬

Get this IPCIF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPCIF vs SCHD IPCIF vs JEPI IPCIF vs O IPCIF vs KO IPCIF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.